Advice
following a full submission:
aclidinium (Eklira Genuair®) is accepted for use within NHS Scotland.
Indication under review: as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
In two phase III studies, aclidinium was statistically superior to placebo in improving lung function (forced expiratory volume in 1 second [FEV1]) after 12 weeks and 24 weeks.
Download detailed advice138KB (PDF)
Medicine details
- Medicine name:
- aclidinium bromide (Eklira Genuair)
- SMC ID:
- 810/12
- Indication:
- As a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
- Pharmaceutical company
- Almirall Ltd
- BNF chapter
- Respiratory system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 12 November 2012